Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.57 |
| ▸ | CDK8 | P49336 | 3/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.57 |
| ▸ | IGF1R | P08069 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | FLT1 | P17948 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.57 |
| ▸ | CLK2 | P49760 | 2/20 | 0.57 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.57 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.57 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.57 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.57 |
| ▸ | CHUK | O15111 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12472076 | 0.79 | ALDH1A1 (0.43) | JAK2CDK8AURKBPRKD3MAP4K4 | |
| SCHEMBL1504356 | 0.79 | AURKB (0.39) | JAK2CDK8AURKBPRKD3MAP4K4 | |
| SCHEMBL1504261 | 0.79 | ALDH1A1 (0.43) | JAK2CDK8AURKBPRKD3MAP4K4 | |
| SCHEMBL1504472 | 0.78 | AURKA (0.63) | JAK2AURKBJAK3RPS6KA3MAPK1 | |
| Hydrochloric Acid SCHEMBL1504709 | 0.77 | AURKA (0.61) | JAK2AURKBJAK3RPS6KA3MAPK1 | |
| SCHEMBL857275 | 0.73 | IKBKB (1.00) | JAK2CDK8AURKBPRKD3MAP4K4 | |
| SCHEMBL31466647 | 0.71 | NUDT1 (0.38) | JAK2PRKD3MAP4K4FGFR1FLT1 | |
| SCHEMBL12127858 | 0.70 | IKBKB (0.93) | JAK2CDK8AURKBPRKD3MAP4K4 | |
| SCHEMBL30557437 | 0.70 | PDPK1 (0.42) | JAK2CDK8AURKBPRKD3MAP4K4 | |
| SCHEMBL15793921 | 0.70 | PDPK1 (0.42) | JAK2CDK8AURKBPRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574863-A | Heterocyclic compounds as JANUS kinase inhibitors | BIOCRYST PHARM INC | 2012-07-11 | — | — | CN | claimed |
| EP-2470537-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-07-04 | — | — | EP | claimed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | claimed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | claimed |
| CN-102574863-A | Heterocyclic compounds as JANUS kinase inhibitors | BIOCRYST PHARM INC | 2012-07-11 | — | — | CN | disclosed |
| EP-2470537-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885CDK8 411/4885AURKB 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.